SYNTHROID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Synthroid, and what generic alternatives are available?
Synthroid is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in SYNTHROID is levothyroxine sodium. There are ten drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Synthroid
A generic version of SYNTHROID was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
Summary for SYNTHROID
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 114 |
Clinical Trials: | 18 |
Patent Applications: | 4,366 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SYNTHROID |
Drug Sales Revenues: | Drug sales revenues for SYNTHROID |
What excipients (inactive ingredients) are in SYNTHROID? | SYNTHROID excipients list |
DailyMed Link: | SYNTHROID at DailyMed |
Recent Clinical Trials for SYNTHROID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
VA Office of Research and Development | Phase 2 |
Central Arkansas Veterans Healthcare System | Phase 4 |
VA Office of Research and Development | Phase 4 |
Pharmacology for SYNTHROID
Drug Class | l-Thyroxine |